TiGenix Licenses to Takeda Ex-US Rights for Stem Cell Treatment – Genetic Engineering & Biotechnology News (blog)
European Pharmaceutical Review |
TiGenix Licenses to Takeda Ex-US Rights for Stem Cell Treatment
Genetic Engineering & Biotechnology News (blog) TiGenix has sold to Takeda ex-U.S. rights to its stem cell treatment Cx601 for complex perianal fistulas in patients with Crohn's disease—an up-to-€390 million ($435 million)-plus deal reflecting what the Belgian biotech called a shift of resources … TiGenix reconfirms its strategic focus on its allogeneic stem cell platforms Takeda inks another biotech pact as it pays $400M+ to TiGenix |
